Jump to content

Brimonidine Phase II Study Group


rss

Recommended Posts

British Journal of Dermatology, 2012 166, pp 633–641

Once-daily topical brimonidine tartrate gel 0Æ5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies

J. Fowler, M. Jarratt, A. Moore, K. Meadows, A. Pollack, M. Steinhoff, Y. Liu and M. Leoni, on behalf of the Brimonidine Phase II Study Group

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...